Rheumnow

ACR22 Daily Recap: Saturday Recap JAK vs TNF inhibitor Infections in RA Opioid and Neuropathic Use After Initiating btsDMARDs in RA Pre-RA Pharmacological Interventions: Delaying is not Enough PreRA to Treat or Not! Prescribing Methotrexate in Post-Roe Era The Great Debate: To Treat or Not to Treat Pre RA To Switch or Not: Biosimilars in Inflammatory Arthritis

ACR22 Year in Review Report Can computers tell the difference between RA & PsA? NSAIDs and CV risk in Inflammatory Arthritis Prelude to a Meeting (ACR22) (11.11.2022) QD205 - RA Activity During Pregnancy (abstract #0955) Sputum anti-CCP the new diagnostic test in at-risk RA? Switching Between JAK Inhibiters in RA Treatment Choices and Mortality in RA ILd

Treatment Considerations in Axial Spondyloarthritis What Happens after you stop biologics? What lifestyle factors affect TNF inhibitor efficacy in AxSpA? Which is better for AxSpA? IL-17i or TNFi? Women vs. Men: Response to Treatment in Seronegative Arthritis

Opioids and Health Care Utilization in PsA and AS Reproductive health in a post-Roe world Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression Sunday (Day 2): ACR 22 Daily Recap Tapering TNFi in nonradiographic AxSpA The CONSUL Trial: Ankylosing Spondylitis

Comorbidities in Ankylosing Spondylitis Early Diagnosis of Axial Spondyloarthritis Fertility issues in SpA Gender in AxSpa Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE JAK inhibitors in rheumatic diseases Opioid use in PsA and SpA

ACR22 Daily Recap: Saturday Recap AI Future of Sacroiliitis Assessment Artificial Intelligence in Detecting Sacroiliitis Axial Spondyloarthritis: gender differences Can we alter neonatal gut microbiome to prevent spondyloarthritis? Comorbidities in Axial Spondyloarthritis Do Disease Activity Measures Really Capture AS in Women?

Dr. Jack Cush and Dr. Arthur Kavanaugh discuss, dissect and deliberate the sessions and data presented at the ACR22 meeting in Philadelphia.

Wednesday - SpA Panelists: Drs. Lianne Gensler, Antoni Chan, Akhil Sood, Eric Dein, Sheila Reyes, Catherine Sims

Get the Skinny on Bimekizumab in PsA Dr. Janet Pope discusses abstract presented at ACR22 Convergence in Philadelphia, PA. L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study Low dose steroids can negatively impact bone healthDr. Janet Pope discusses abstract L01 presented at ACR22 Convergence in Philadelphia, PA.  L01: Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study The First Head to Head trial in Axial Spondyloarthritis Dr. Lianne Gensler discusses abstract L15 presented at ACR22 Convergence in Philadelphia, PA. L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study Why Clinical Trials? Dr. Guillermo Valenzuela talks about the

RheumNow faculty to recap the best and most interesting data presented at ACR2022 in the area of PsA. Tuesday - PsA (7pm ET) Panelists: Drs. Rachel Tate, Robert Chao, Olga Petryna, Elaine Husni, Patricia Harkins

RheumNow faculty recap the best and most interesting data presented at ACR22 in RA. Panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan

Autoimmunity Following COVID-19 Infection Dr. Akhil Sood discusses abstract 0795 at ACR22 Convergence. Abstract 0795: Post-Acute COVID-19 Sequalae (PACS) with New-onset Rheumatological Complications Best of ACR22 in PsA: Day Three Dr. Rachel Tate discusses the best PsA content presented on day three (Monday) at ACR22 Convergence in Philadelphia, PA. Medication Adherence intervention in SLE Dr. Bella Mehta speaks with Dr. Kai Sun abstract 0063 at ACR22 Convergence in Philadelphia, PA. Abstract 0063: Implementability of a SLE Medication Adherence Intervention Peresolimab for RA: Phase 2a Results Dr. Jonathan Kay abstract L03 at ACR22 Convergence in Philadelphia. L03: A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis

ACR 2022 Daily Recap for Monday, November 14th.

Breakthrough COVID infection in RMD patients treated with Evusheld Dr. Yuz Yusof talks with Dr. Chris Podgorski at ACR22 Convergence. Lung Involvement in VEXAS Dr. Yuz Yusof and Dr. Marta Casal Moura discusses abstract 1569 presented at ACR22 Convergence.  Abstract 1569: Lung Involvement in VEXAS Syndrome Reproductive health in a post-Roe world Dr. Robert Chao discusses abstract 1673 and L09 presented at ACR22 Convergence.  Abstract 1673: Preconceptional NSAID Treatment Exposure Is Associated with a Significantly Longer Time-to-conception in Women with Spondyloarthritis: Analysis of the Prospective GR2 Cohort Abstract L09: Impact on Access to Methotrexate in the Post-Roe Era Stop Ordering Repeat ANAs! Dr. Kathryn Dao reviews abstracts 1278, 0228, and 0058 presented at ACR22 Convergence. Ultrasound in PsA Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound En

Bouncebackability portends increased risk of adverse outcomes in RA Dr. Richard Conway discusses Abstract 2218 at ACR22 Convergence. Abstract 2218: Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis Deucravacitinib in PsA Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial Efficacy and Safety Results from BE OPTIMAL in PsA Dr. Arthur Kavanaugh discusses abstract L02 ACR22 Convergence in Philadelphia, PA.  L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study Hydroxychloroquine Update from ACR22 Dr. Michelle Petri reviews several abstracts presented at ACR22 Convergence. Ab

Comorbidities in Axial Spondyloarthritis Dr. Antoni Chan discusses Abstract 1609 at ACR22 Convergence. Diffuse alveolar hemorrhage in antiphospholipid syndrome Dr. Eric Dein discusses Abstract 0675 at ACR22 Convergence. Abstract 0675: Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort Eosinophilia in systemic JIA patients after exposure to biologics Dr. Bella Mehta discusses Abstract 0872 at ACR22 Convergence. Abstract 0872: Incidence, Risk Factors, and Outcomes of Eosinophilia on IL-1 and IL-6 Inhibitors in Systemic and Non-Systemic Juvenile Idiopathic Arthritis Gender differences in Axial Spondyloarthritis Dr. Antoni Chan covered abstracts 0497 and 1614 at ACR22 Convergence in Philadelphia, PA. Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE Dr. Sheila Reyes discusses abstract 1654 at ACR22 Convergence.  Abstract 1654: Hydroxychloroquine Dosing Le

Best of ACR Day Two in PSA Dr. Rachel Tate, discusses abstracts 1018, 1159 at ACR22 Convergence. Comorbidities in Ankylosing Spondylitis Dr. Akhil Sood discusses Abstract 1609 at ACR22 Convergence. Fat and bone are never alone: osteoporotic fracture in RA Dr. David Liew discusses Abstract 889 at ACR22 Convergence.  Abstract 889: Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis GCA: What we feel and what we can't Dr David Liew discusses Abstracts 0483 and 0486 at ACR22 Convergence. Hydroxychloroquine: Cumulative Doses and Thresholds Dr. Sheila Reyes discusses Abstracts 0982 and 0344 at ACR22 Convergence. JAK inhibitors in rheumatic diseases Dr. Antoni Chan discusses abstracts 0510 and 0404 at ACR22 Convergence in Philadelphia, PA. Abstract 0510: MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Abstract 0404: Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with A

Join RheumNow faculty to recap the best and most interesting data presented at ACR22 in the area of SLE.  Sunday - SLE Panelists: Drs. Kathryn Dao, Bella Mehta, Yuzaiful Yusof, Eric Dein, Michael Putman, Sheila Reyes, Janet Pope

ACR 2022 Daily Recap for Sunday, November 13th.